100% cure rate for people with HCV genotype 1 treated with AL-335, odalasvir and simeprevir for 6 or 8 weeks

Liz Highleyman
Published:
05 October 2016

A triple regimen containing two experimental hepatitis C drugs – AL-335 and odalasvir – plus simeprevir taken for either 6 or 8 weeks cured all participants with previously untreated genotype 1 hepatitis C 1 who did not have cirrhosis in a small study, while a dual regimen without simeprevir cured 90%, according to findings presented last month at New Perspectives in Hepatitis C Virus Infection – The Roadmap for Cure in Paris. The conference was organised by the European Association for the Study of the Liver (EASL).

Direct-acting antiviral therapy that combines drugs targeting different steps of the hepatitis C virus (HCV) lifecycle – usually taken for 12 weeks – is highly effective, but researchers continue to explore new combinations that can be used for a shorter duration, thereby improving convenience and reducing cost. Ideally such therapy would be pangenotypic, meaning it is active against all HCV genotypes and can be used throughout the world without the need for prior genotypic testing.

Edward Gane of the University of Auckland and colleagues evaluated the pharmacokinetics, safety and efficacy of regimens containing the investigational HCV polymerase inhibitor AL-335, being developed by Alios BioPharma (a subsidiary of Janssen), Achillion's pangenotypic second-generation NS5A inhibitor odalasvir (formerly ACH-3012) and Janssen's approved HCV protease inhibitor simeprevir (Olysio).

Glossary

compensated cirrhosis

The earlier stage of cirrhosis, during which the liver is damaged but still able to perform most of its functions. See also ‘cirrhosis’ and ‘decompensated cirrhosis’.

FibroScan

A non-invasive test, used instead of a biopsy, to measure the stiffness or elasticity of the liver using an ultrasound probe.

qd

Abbreviation of a Latin term meaning once every day.

Early studies of AL-335 demonstrated potent antiviral activity even against drug-resistant HCV, and viral load reductions of up to 4.8 log10 IU/ml in a 7-day monotherapy study. In 2014 Prof. Gane reported high cure rates in a phase 2 trial evaluating odalasvir plus Gilead Sciences' approved HCV polymerase inhibitor sofosbuvir (Sovaldi) in people with previously untreated genotype 1 HCV.

The current ongoing phase 2a study will include up to 16 cohorts of 20 participants each, testing various dosing regimens of AL-335 plus odalasvir, with or without simeprevir, taken for 6 or 8 weeks.

Last week's presentation covered the first four cohorts, which enrolled an easier-to-treat population of people with previously untreated genotype 1 HCV without liver cirrhosis. People with genotype 3 and those with compensated cirrhosis are included in later cohorts.

This interim analysis included 80 people with chronic hepatitis C who had not taken hepatitis C treatment before (treatment naive). About two-thirds were men, most were white and the mean age was about 53 years. About 80% had harder-to-treat HCV genotype 1a, the rest 1b, with a mean baseline HCV viral load of about 6.2 log10 IU/ml. The average FibroScan liver stiffness score was approximately 6.0 kPa, suggesting mostly mild to moderate fibrosis.

Participants in this open-label study received AL-335 at doses of 400 or 800mg once-daily (QD), odalasvir at 50mg once-daily or every-other-day (QOD), and simeprevir at 75 or 100mg once-daily. They were allocated to four cohorts:

  • Cohort 1: AL-335 400mg QD + odalasvir 50mg QD + simeprevir 100mg QD for 8 weeks;
  • Cohort 2: AL-335 800mg QD + odalasvir 50mg QOD for 8 weeks (no simeprevir);
  • Cohort 3: AL-335 800mg QD + odalasvir 50mg QOD + simeprevir 75mg QD for 8 weeks;
  • Cohort 4: AL-335 800mg QD + odalasvir 50mg QOD + simeprevir 75mg QD for 6 weeks.

In the three cohorts receiving triple therapy, 100% of participants achieved sustained virological response at 12 weeks after completing treatment (SVR12).

In the dual therapy cohort that did not receive simeprevir, the SVR12 rate fell to 90%. The two people who experienced relapse in this cohort developed NS5A mutations that confer resistance to odalasvir.

Treatment was generally safe and well tolerated. There was one serious adverse event leading to treatment discontinuation: an atrioventricular block (a type of heart rhythm abnormality) considered probably related to the study drugs.

A majority of adverse events were mild, with the most common being headache (18 reports), fatigue (15), respiratory tract infections (11) and bruising (9). There were few grade 3 or higher laboratory abnormalities and no clinically relevant echocardiogram changes.

Based on these findings, the researchers concluded that AL-335 + odalasvir with or without simeprevir “was highly effective in treatment-naive patients with HCV genotype 1 without cirrhosis”. They added that these results support evaluation of triple combinations in people with genotype 3 or cirrhosis.

A larger phase 2b trial (NCT02765490) evaluating 800mg AL-335 + 25mg odalasvir + 75mg simeprevir, all once-daily for 6 or 8 weeks, is expected to begin enrolment this autumn for treatment-naive and treatment-experienced people without cirrhosis who have HCV genotypes 1, 2, 4, 5 and 6.

Reference

Gane E et al. Short duration treatment with AL-335 and odalasvir (ODV), with or without simeprevir (SMV), in treatment naïve patients with hepatitis C virus (HCV) genotype (GT) 1 infection. New Perspectives in Hepatitis C Virus Infection – The Roadmap for Cure, Paris, abstract 178, 2016.